

## PAD VOLUME I

### References (First and Last Pages)

1. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. *Circulation* 1996; 94:3026-49.
2. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999; 340:115-26.
3. Vogt MT. Peripheral arterial disease: the epidemiology and burden of disease in older women. Continuing Medical Education (CME) Monograph on the Society for Vascular Medicine and Biology (SVMB) website. [Cited 2002]. Available at <http://www.svmb.org/medpro/cme/cme01.html>.
4. McDermott MM, Fried L, Simonsick E, et al. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning. *Circulation* 2000;10: 1007-12.
5. McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the walking and leg circulation study. *Ann Intern Med* 2002; 136: 873-83.
6. Gerhard-Herman MD, Wittgen CM. Treatment and outcomes of peripheral atherosclerosis in women. CME Monograph on the SVMB website. [Cited 2002]. Available at <http://www.svmb.org/medpro/cme/cme01.html>.
7. Ouriel K. Peripheral arterial disease. Seminar. *Lancet* 2001; 358: 1257-64.
8. Jaff MR. Severe peripheral arterial disease and critical limb ischemia: incidence, pathophysiology, presentation, methods of diagnosis. CME Monograph on the SVMB website. [Cited 2002]. Available at <http://www.svmb.org/medpro/cme/cme01.html>.
9. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly. The Rotterdam Study. *Arterioscler Thromb Vasc Biol* 1998; 18: 185-92.
10. Schainfeld RM. Management of peripheral arterial disease and intermittent claudication. *J Am Board Fam Pract* 2001; 14(6): 443-5.
11. TransAtlantic Inter-Society Consensus (TASC) Working Group. Epidemiology, natural history, risk factors: TASC document. *J Vasc Surg* 2000; 31(suppl): S23.

147. Otsuka America Pharmaceutical, Inc., Pharmacia & Upjohn Corp. [Internet]. Pletal prescribing information (package insert). [Cited 2002 Oct]. Available at [http://www.pletal.com/pro/0\\_7.asp](http://www.pletal.com/pro/0_7.asp).
148. Aventis Pharmaceutical, Inc. [Internet]. Trental prescribing information (package insert). [Cited 2002 Oct]. Available at [http://www.aventis-us.com/PIs/trental\\_TXT.html](http://www.aventis-us.com/PIs/trental_TXT.html).
149. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. *J Gen Intern Med* 1997; 12: 209-15.
150. Levy PJ, MacClenahan K, Ferrario CM, Yunis C. Secondary prevention is inferior in patients with peripheral arterial disease. *J Am Coll Cardiol* 2002; 39: Suppl A. Abstract: 1179-79. [Internet]. Available at <http://www.cardiosource.com/library/journals/journal/accabstracts?sdid=4884>.
151. Mukherjee D, Lingam P, Chetcuti S, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions. Insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI<sup>2</sup>). *Circulation* 2002; 106(15): 1909-12. Abstract.
152. Mulkay KT, Benjamin ME, Lilly MP, et al. The prevalence of lipid lowering therapy in patients undergoing infrainguinal bypass. The Society for Vascular Medicine and Biology. 12<sup>th</sup> Annual Meeting & Postgraduate Symposium. Poster presentation P16. [Internet]. Available at <http://www.svmb.org/medpro/events/annualmeeting/meeting3.html>.
153. Nass CM, Allen JK, Jermyn RM, Fleisher LA. Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral arterial disease. *Vasc Med* 2001; 6: 35-41.
154. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. *Vital Health Stat* 10(200). 1999.
155. 2002 Drug Topics Red Book. Montvale (NJ). Thompson Medical Economics; 2002.
156. Kaplan NM. Angiotensin II receptor antagonists in the treatment of hypertension. *Am Fam Physician* 1999; 60 (4): 1185-90.
157. Ward MR, Pasterkamp G, Yeung AC, Borst C. Arterial remodeling mechanisms and clinical implications. *Circulation* 2000; 102: 1186-91.